Aghajanian, Carol
Bell-McGuinn, Katherine M.
Burris, Howard A. III
Siu, Lillian L.
Stayner, Lee-Ann
Wheler, Jennifer J.
Hong, David S.
Kurkjian, Carla
Pant, Shubham
Santiago-Walker, Ademi
Gauvin, Jennifer L.
Antal, Joyce M.
Opalinska, Joanna B.
Morris, Shannon R.
Infante, Jeffrey R.
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
Article History
Received: 15 February 2018
Accepted: 15 March 2018
First Online: 3 April 2018
Compliance with ethical standards
:
: C. Aghajanian declares she participated on a Focus Study Steering Committee for Mateon Therapeutics and has served on the Advisory Boards of Clovis, Cerulean Pharma, Bayer, and VentiRx at various time points since July 2015. K. M. Bell-McGuinn declares she is currently an employee and stockholder of Eli Lilly. H. A. Burris III declares he has no conflict of interest. L. L. Siu declares she has received research funding from GlaxoSmithKline. L. Stayner declares she has no conflict of interest. J. J. Wheler declares she has no conflict of interest. D. S. Hong declares he has received research funding from Adaptimmune, Abbvie, Amgen, AstraZeneca, Bayer, BMS, Daiichi-Sanko, Eisai, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa, Eli Lilly, LOXO, Mirati, Merck, Medimmune, Molecular Template, Novartis, Pfizer, and Takeda; D. S. Hong has also received consulting fees from Bayer, Baxter, Guidepoint Global, and Janssen; D. S. Hong has also received travel accommodations from LOXO and Mirna, and has ownership interest in Molecular Match and Oncoresponse. C. Kurkjian declares she has no conflict of interest. S. Pant declares he has no conflict of interest. A. Santiago-Walker declares she has received personal fees from GlaxoSmithKline. J. L. Gauvin declares she has received personal fees and has stock in GlaxoSmithKline. J.M. Antal declares she holds stock in GlaxoSmithKline and is an employee and holds stock in G1 Therapeutics. J.B. Opalinska declares she was an employee and owns stock in GlaxoSmithKline. S.R. Morris declares she was an employee of and has patent interest with GlaxoSmithKline. J.R. Infante declares he is an employee of Johnson & Johnson.
: This study was funded by GlaxoSmithKline (NCT number: NCT00920257).Drs. Aghajanian and Bell-McGuinn (while at MSK) are supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.